About

Autifony Therapeutics is dedicated to developing new drugs to treat rare CNS disorders using pioneering science

“Autifony Therapeutics Limited is a UK-based company formed in 2011 as a spin-out from GlaxoSmithKline by Charles Large and Giuseppe Alvaro, previously Directors in GSK’s Neuroscience Centre of Excellence for Drug Discovery.

Autifony is using its pioneering expertise in ion channels to develop novel treatments for serious rare and genetic disorders of the central nervous system, such as Fragile X, Progressive Myoclonic Epilepsy and Amyotrophic Lateral Sclerosis, as well as other more common and devastating neuropsychiatric disorders, including Schizophrenia and Bipolar Disorder.

The company is also one of the leaders in pharmaceutical approaches to the treatment of hearing disorders. Hearing disorders affect a significant proportion of the population, and while devices such as hearing aids and cochlear implants can ease the problems for some, many people suffer silently. As well as causing social isolation and distress, hearing loss also brings with it a considerable economic cost to society, with increased risk of unemployment, the need for carer support, and other costs.”

 

Management Team & Board of Directors


Investors

Autifony Therapeutics Limited is a privately funded company. The main investors are:

Additional Funding

Additional Funding for Autifony has also been obtained from UCL Business and from The International Biotechnology Trust (IBT) and from the Dementia Discovery Fund.

Related News

20Jul

Charles Large to speak at ‘Fragile X syndrome webinar – in pursuit of a cure’ World Fragile X Day

0 Comments
Autifony CEO Charles Large will be speaking at the webinar ‘Fragile X syndrome – in pursuit of a cure’ World... Read More →
07May

Autifony presents key efficacy data for AUT00206 from a first-in-patient safety/PK study in patients with schizophrenia at the Schizophrenia International Research Society annual meeting

0 Comments
Stevenage 16th April – This weekend Dr Charles Large will present key biomarker efficacy data from a first study of... Read More →
04Mar

Autifony Therapeutics, Boehringer Ingelheim to collaborate on novel ion channel target with potential in multiple disease areas related to lysosomal storage disorders

0 Comments
Stevenage, UK – 04 March 2021 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
26Aug

Autifony Therapeutics regains rights to clinical stage Kv3 programme

0 Comments
Stevenage, UK – 26 August 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
04May

Autifony Therapeutics announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing disorders

0 Comments
Stevenage, UK – 04 May 2020 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments... Read More →
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image